Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.46 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.45 |
| ▸ | NEK3 | P51956 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | NEK5 | Q6P3R8 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13362699 | 0.87 | BRAF (0.51) | BRAFLRRK2RAF1PTK2JAK2 | |
| SCHEMBL1633567 | 0.85 | BRAF (0.54) | BRAFAURKALRRK2STK17AMYLK4 | |
| SCHEMBL1633936 | 0.83 | TBK1 (0.47) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL1867468 | 0.82 | STK17A (0.53) | BRAFAURKASTK17AMYLK4NEK3 | |
| SCHEMBL13252791 | 0.80 | AURKA (0.46) | BRAFAURKALRRK2STK17AMYLK4 | |
| SCHEMBL1867038 | 0.80 | LRRK2 (0.53) | LRRK2JAK2 | |
| SCHEMBL1865435 | 0.79 | LRRK2 (0.47) | BRAFAURKALRRK2STK17AMYLK4 | |
| SCHEMBL1871929 | 0.79 | CA2 (0.49) | — | |
| SCHEMBL1634024 | 0.78 | AURKA (0.51) | BRAFAURKALRRK2STK17AMYLK4 | |
| SCHEMBL1633534 | 0.77 | AURKA (0.56) | BRAFAURKASTK17AMYLK4NEK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | claimed |
| US-8716478-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 316/4885AURKA 588/4885LRRK2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.